Healthcare Providers and Services
Company Overview of N-of-One Therapeutics, Inc.
N-of-One Therapeutics, Inc. provides clinical analysis, curation, and interpretation of a tumor's molecular profile to providers, diagnostic companies, individual physicians, and cancer patients. The company’s solutions include treatment strategy roadmaps, clinical trial matching, and diagnostic strategy roadmaps. Its solutions and services pivot on matching patient-specific tumor molecular profiling data with knowledge on diagnostic technologies and therapeutic options to identify relevant clinical strategies for each patient's unique cancer. The company supports oncologists by delivering content and clinical insights for cancer treatment decisions and diagnostic approaches. N-of-One Therap...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One Therapeutics, Inc.
Chairman and Chief Executive Officer
Founder, President, Chief Medical Officer and Director
Vice President of Operations
Compensation as of Fiscal Year 2015.
N-of-One Therapeutics, Inc. Key Developments
CompanionDx Selects N-of-One’s Cost-effective, High-quality Clinical Interpretation for Targeted Next-generation Sequencing Tests
Jul 22 15
N-of-One, Inc. announced that CompanionDx, a CLIA certified, high-complexity laboratory specializing in integrated genomic solutions, combining diagnostics such as next-generation sequencing, pharmacogenomics and drug monitoring, signed an agreement with N-of-One for N-of-One to provide clinical interpretation for both CompanionDx's focused and comprehensive oncology panels. Financial terms of the agreement are not disclosed. CompanionDx's next-generation sequencing evaluates the DNA in a patient's tumor via a small biopsy sample. The DNA is analyzed for key changes or somatic mutations. When combined with the company's pharmacogenomics testing, which establishes a clear understanding of the patient's potential for metabolizing a drug based on their possible germline variants, CompanionDx can help increase the efficacy of prescribed therapy creating a safer, more effective and more personalized approach to cancer treatment.
CellNetix Pathology and Laboratories Utilizes N-of-One TrialMatch
May 26 15
N-of-One reported that CellNetix Pathology and Laboratories has adopted N-of-One's new clinical trial matching solution, TrialMatch, as well as N-of-One clinical interpretation evidence services. Under this agreement, N-of-One will provide clinical interpretation evidence as well as molecular profile-based clinical trial matching for CellNetix next generation sequencing cancer genomics tests.
N-of-One to Provide CNV Analysis Interpretation for Affymetrix’s OncoScan Kit
May 11 15
N-of-One has signed a business partner agreement to provide copy number variation (CNV) analysis interpretation for Affymetrix's OncoScan assay kit customers. Under the agreement, N-of-One will work closely with Affymetrix to ensure data from the OncoScan assay, combined with its interpretation, optimise the value of tumour profiling based on CNV analysis for clinicians. Based on Affymetrix's novel molecular inversion probe (MIP) technology, OncoScan assay helps in obtaining genome-wide copy number and loss-of-heterozygosity (LOH) profiles from degraded formalin-fixed, paraffin-embedded-derived tumour DNA samples.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|